公司主营收入主要来自医药商业，占比达98.90%，其中：批发-医疗客户：29.72亿元，占比57.72%，毛 利率为6.74%。批发-商业客户：11.46亿元，占比22.26%，毛利率为3.13%。零售：9.74亿元，占比 18.91%，毛利率为15.38%。其他：3573.03万元，占比0.69%，毛利率为26.63%。 财务指标变动原因 近期人民同泰(600829)发布2025年中报，证券之星财报模型分析如下： 经营概况 人民同泰(600829)发布的2025年中报显示，公司营业总收入为51.49亿元，同比上升3.29%。然而，归母 净利润仅为7257.92万元，同比下降46.31%，扣非净利润为7244.14万元，同比下降41.2%。这表明公司 在收入增长的同时，盈利能力显著下降。 单季度数据 第二季度营业总收入为24.83亿元，同比上升3.98%，但归母净利润仅为2673.83万元，同比下降 52.97%，扣非净利润为2731.4万元，同比下降40.72%。这进一步凸显了公司在盈利方面的压力。 主要财务指标 毛利率：8.04%，同比下降11.4%。净利率：1.41%，同比下降48.02%。三费占营收比 ...

证券代码：600436 证券简称：片仔癀 公告编号：2025-014 漳州片仔癀药业股份有限公司 根据《上海证券交易所上市公司自律监管指引第3号——行业信息披 露》（2022年修订）《上市公司行业信息披露指引第六号——医药制造》 （2022年修订）等相关法律法规，漳州片仔癀药业股份有限公司（以下简 称"公司"）现将2025年第一季度主要经营数据披露如下： 一、 公司 2025 年第一季度主营业务分行业情况 1 / 4 单位：万元 人民币 行业 主营业务 收入 主营业务 成本 毛利率 （%） 主营业务 收入增长 率（%） 主营业务 成本增长 率（%） 毛利率增 减情况 医药 制造业 187,387.69 70,765.30 62.24 13.31 44.95 减少8.24 个百分点 医药 流通业 101,395.09 90,529.53 10.72 -19.11 -15.38 减少3.93 个百分点 医药行 业小计 288,782.78 161,294.83 44.15 -0.67 3.52 减少2.26 个百分点 化妆品业 19,724.96 6,440.66 67.35 -1.17 1.68 减少0.91 ...

Core Viewpoint - The company plans to retain undistributed profits for business development in 2025 and will not distribute profits or increase capital reserves for the current year [2][29]. Company Overview - The company operates in the pharmaceutical distribution industry, which is crucial for the national healthcare system and health industry, playing a vital role in the pharmaceutical supply chain [2]. - The company is the largest pharmaceutical distribution company in Heilongjiang Province, with a significant presence in both wholesale and retail sectors [12][13]. Industry Situation - The pharmaceutical distribution industry in China has shown stable growth, with the total sales scale reaching 2.93 trillion yuan in 2023, a year-on-year increase of 7.5% [3]. - The pharmaceutical wholesale market sales reached 2.29 trillion yuan in 2023, also reflecting a 7.5% year-on-year growth [4][5]. - The retail pharmaceutical market sales amounted to 640.2 billion yuan, with a year-on-year growth of 7.6% [6]. Industry Characteristics - The pharmaceutical distribution industry exhibits stable demand characteristics, with limited seasonal fluctuations and low sensitivity to macroeconomic cycles [8]. - The industry is characterized by regional differences, with companies that have strong distribution capabilities and a wide range of products enjoying competitive advantages [8]. Regulatory Environment - The government has introduced several reforms aimed at optimizing resource allocation and ensuring public medication safety, including centralized procurement and medical insurance payment reforms [9][10]. - The 2024 focus includes enhancing the transparency of drug pricing and promoting fair competition among pharmacies [9][10]. Company Financial Performance - In the reporting period, the company achieved operating revenue of 1,004.83 million yuan, a decrease of 3.29% year-on-year, and a net profit attributable to shareholders of 21.33 million yuan, down 27% year-on-year [19]. - The company's main business revenue was 1,000.72 million yuan, with wholesale business revenue of 822.80 million yuan and retail business revenue of 169.13 million yuan [19]. Business Operations - The company’s wholesale business primarily serves medical clients, including public hospitals and private medical institutions, while the retail business focuses on direct sales through chain pharmacies [14][16]. - The company has established strong partnerships with various pharmaceutical manufacturers, ensuring stable procurement channels [15].